Obese AdultsSVTNCT07729215
Evaluation of the Effects of Systemic Vibration Therapy on Thermogenesis, Cardiovascular Parameters, Endocrine-inflammatory Markers, and Physical-functional Performance in Adults With Obesity.
A study testing Systemic vibratory therapy and Systemic vibration therapy in people with Obese Adults, run by Laboratorio de Vibraçoes Mecanicas e Praticas Integrativas at 1 site in Brazil.
Trial summary
The goal of this clinical trial was to evaluate the effects of Systemic Vibration Therapy (SVT) on thermogenesis, cardiovascular health, endocrine-inflammatory markers, and physical performance in adults (men and women, aged 18-59) with obesity. Read more about this study
- Who is it for?
- Ages 18 to 59 years
- Conditions the study is for
- Obese Adults
- What is being tested?
- Systemic vibratory therapy and Systemic vibration therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteBrazil
- Study dates
- 31 Oct 2024to 31 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 59 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Individuals aged 18 to 59 years;
- Both sexes;
- Diagnosis of obesity, defined as a body mass index (BMI) ≥ 30 kg/m²;
- Waist-to-height ratio (≥ 0.50).
Who cannot join
- Presence of metallic prostheses;
- Presence of a pacemaker;
- Uncontrolled and untreated hypertension (≥180/120 mmHg);
- History of labyrinthitis;
- Previous diagnosis of deep vein thrombosis;
- Pregnancy;
Show all 9Show fewer
- Recent surgery (within the previous 6 months);
- Neurodegenerative, pulmonary, or infectious diseases;
- Inability to undergo the proposed assessments and/or interventions.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Laboratório de Vibrações Mecânicas e Práticas Integrativas - Policlínica Universitária Piquet Carneiro
Rio de Janeiro, Rio de Janeiro, 20950-003
About this study
The goal of this clinical trial was to evaluate the effects of Systemic Vibration Therapy (SVT) on thermogenesis, cardiovascular health, endocrine-inflammatory markers, and physical performance in adults (men and women, aged 18-59) with obesity. The main questions it aimed to answer were:
What were the effects of SVT on thermogenesis and physical-functional performance in people with obesity?
Read more
How did SVT affect cardiovascular risk, hormone levels, and inflammation?
Researchers compared two types of vibrating platforms (vertical and side-alternating) to a placebo group (where the platform was turned off but simulated the sound) to see if the vibration led to changes in these health parameters.
Participants:
Attended sessions 2 times per week for either 6 or 12 weeks.
Stood barefoot in a static squat position on a vibrating platform for 29 minutes per session (alternating 1 minute of vibration with 1 minute of rest).
Underwent health assessments, including blood tests, body composition scans, muscle strength tests, and quality of life questionnaires.
Read the detailed description
Obesity is characterized by the excessive accumulation of body fat and triggers systemic impacts. Currently, it affects 1 in 8 people worldwide, with projections of generating global costs of US$ 3 trillion per year by 2030. In Brazil, prevalence may reach 30.4%. Central obesity is associated with chronic inflammation, insulin resistance, metabolic dysfunctions, and an increased risk of cardiovascular diseases (CVD), which are the leading causes of death globally. Low-grade inflammation and alterations in the autonomic nervous system also exacerbate cardiovascular risk. In this context, brown adipose tissue, with its thermogenic function, has been studied as a potential ally in body mass control. Excess fat combined with muscle mass loss accentuates functional impairments. Although physical exercise is essential, low adherence among individuals with obesity requires viable alternatives. Systemic vibration therapy (SVT), which utilizes mechanical vibrations through vibrating platforms, emerges as a promising strategy, with evidence of effects on reducing body fat, increasing muscle strength, and modulating hormonal and neuromuscular responses. However, conclusive evidence regarding the best protocols is lacking, justifying further studies.This study aims to evaluate the effects of SVT on thermogenesis, cardiovascular, endocrine-inflammatory parameters, and the physical-functional performance of adults with obesity by applying different protocols. Individuals aged 18 to 59 of both sexes, with a BMI ≥ 30 kg/m² and WHR ≥ 0.50, will be included. Recruitment will take place at HUPE, PPC/UERJ, the general community, and social media. The sample size calculation indicated a need for 30 participants, accounting for potential dropouts. Personal information will be collected, and biochemical, endocrine-inflammatory, vascular, cardiovascular risk, body composition, muscle strength, electromyography, physical-functional tests, eating behavior, quality of life, cognition, sleep, vital signs, and perceived exertion assessments will be performed.Interventions will occur twice a week, with a 72-hour interval, for 6 and 12 weeks. Two types of vibrating platforms will be used: vertical displacement (VVP) and side-alternating displacement (AVP). Three protocols will be applied: the GAVP will use the AVP with a frequency of 30 Hz and an amplitude of 2.5 mm or 5.0 mm; the GVVP will use the VVP, also at 30 Hz with "low" amplitude; and the SG (Sham Group) will perform the same movements with the platform turned off, simulating the vibration sound. In all groups, participants will be barefoot, in a static squat with knees at $50^\circ$, for 1 minute of exposure followed by 1 minute of rest, repeated 15 times, totaling 29 minutes per session.
- Conditions
- Obese Adults
- Being tested
- Systemic vibratory therapy, Systemic vibration therapy
- Keywords
- whole-body vibration, systemic vibratory therapy, obesity, functionality, cardiovascular risk, muscle strength, body composition, adults, anthropometry
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Systemic vibratory therapyDevice
Also called vibrating platform
The vertical displacement vibrating platform (Power Plate Pro 5, North America, Inc.) used features triplanar movement of its base (up and down, right and left, and forward and backward movements). However, the resultant of these movements is vertical; therefore, the individual felt as if it performed only the up and down movement while undergoing systemic vibration therapy. In this equipment, the frequency could be adjusted, and the amplitude was selected according to the chosen frequency, such as "high" or "low." The side-alternating displacement vibrating platform (KIKOS FITNESS, model P204IXC, São Paulo) that was used features base movements like a "seesaw," where the right side rises while the left side lowers and vice versa (in relation to the central fulcrum). On this equipment, the individual felt as if they were on a "seesaw." On this vibrating platform, the frequency could be adjusted, and the amplitude was selected according to the positioning of the individual's.
Systemic vibration therapyDevice
Also called vibrating platform
The individual was positioned barefoot, standing on the base of the side-alternating vibrating platform. The vibrating platform was turned off and coupled with a device that simulated the sound of mechanical vibration.
| Study group | Role | What they receive |
|---|---|---|
| Side-Alternating Vibratory Platform Group (SAVPG) | Active comparator | Systemic vibration therapy was performed on a vibrating platform with side-alternating displacement of the base, at a frequency of 30 Hz, with the peak-to-peak displacement adjusted to 2.5 mm or 5.0 mm. The individual was positioned barefoot, standing on the base of the vibrating platform, with the knees flexed at 50° (measured with a goniometer), in a static squat consisting of 1 minute of exposure to vibration followed by 1 minute of rest. This sequence was performed 15 times, totaling 29 minutes. Receives: Device: Systemic vibratory therapy |
| Vertical Vibratory Platform Group (VVPG) | Active comparator | Systemic vibration therapy was performed on a vibrating platform with vertical displacement of the base, and the individual was positioned barefoot, standing on the base of the vibrating platform with the knees flexed at 50° (measured with a goniometer), at a frequency of 30 Hz, with the amplitude adjusted to "low." The participant was positioned in a static squat, consisting of 1 minute of exposure to mechanical vibration followed by 1 minute of rest. This sequence was performed 15 times, totaling 29 minutes. Receives: Device: Systemic vibratory therapy |
| Control group (CG) | Placebo comparator | The individual was positioned barefoot, standing on the base of the side-alternating vibrating platform, with the knees flexed at 50° (measured with a goniometer). The vibrating platform was turned off and coupled with a device that simulated the sound of mechanical vibration. The volunteer performed the simulation in a static squat, consisting of 1 minute of exposure with the device turned on followed by 1 minute of rest with the device turned off. This sequence was performed 15 times, totaling 29 minutes. Receives: Device: Systemic vibration therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Thermogenin
Thermogenin (Uncoupling Protein 1 [UCP1]) was measured before and immediately after the WBV session. Blood samples were collected by a trained professional at the PPC/UERJ Clinical Analysis Laboratory (Capsule Unit), always during the same morning shift and no later than 8:00 a.m. For peripheral blood assays, serum and plasma collection tubes were centrifuged at 2,000 rpm at 25°C. Subsequently, 500 µL of serum was aliquoted into two microtubes and stored at -80°C until analysis. Serum UCP1 concentrations were determined using a specific enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. Optical density (OD) was measured using a Thermo Scientific spectrophotometer.
Measured: Baseline, Week 6, and Week 12
Endocrine-inflammatory profile
The endocrine-inflammatory profile was assessed by measuring Interleukin-1 beta (IL-1β), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Tumor Necrosis Factor-alpha (TNF-α), Soluble TNF Receptor Type I (sTNF-RI), Soluble TNF Receptor Type II (sTNF-RII), adiponectin, resistin, leptin, and irisin. Blood samples were collected by a trained professional at the PPC/UERJ Clinical Analysis Laboratory (Capsule Unit), always during the same morning shift and no later than 8:00 a.m. For peripheral blood assays, serum and plasma collection tubes were centrifuged at 2,000 rpm at 25°C. Subsequently, 500 µL of serum was aliquoted into two microtubes and stored at -80°C until analysis. Biomarker concentrations were determined using specific enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions. Optical density (OD) was measured using a Thermo Scientific spectrophotometer.
Measured: Baseline, Week 6, and Week 12
Secondary outcomes (13)
Total Body Water
Total Body Water (TBW) was assessed using a tetrapolar bioelectrical impedance analyzer (InBody 370, BIOSPACE, Republic of Korea). The analyzer measured impedance across five body segments (right arm, left arm, trunk, right leg, and left leg) at three frequencies (5, 50, and 500 kHz) and provided segmental body composition measurements, including total body water.
Unit of Measured: in liters (L).
Measured: Baseline, Week 6, and Week 12
Lean Body Mass, Fat Mass, and Skeletal Muscle Mass
The measures of body composition were analyzed using a Tetrapolar Bioelectrical Impedance Analyzer (InBody 370, BIOSPACE, Republic of Korea). The analyzer measured impedance across five body segments (right arm, left arm, trunk, right leg, and left leg) using three different frequencies (5, 50, and 500 kHz) and provided separate body mass readings for each segment. The following body composition components were measured:
Lean Body Mass: Measured in kilograms (kg).
Fat Mass: Measured in kilograms (kg).
Skeletal Muscle Mass: Measured in kilograms (kg).
Measured: Baseline, Week 6, and Week 12.
Body Fat Percentage
The Body fat percentage of the body composition will be analyzed using a Tetrapolar Bioelectrical Impedance Analyzer (InBody 370, BIOSPACE, Republic of Korea). The analyzer performs impedance measurements across five body segments (right arm, left arm, trunk, right leg, and left leg) using three different frequencies (5, 50, and 500 kHz), and provides separate body mass readings for each segment.
Unit of measure: Expressed as a percentage (%).
Measured: Baseline, Week 6, and Week 12
Basal Metabolic Rate
Basal Metabolic Rate will be analyzed using a Tetrapolar Bioelectrical Impedance Analyzer (InBody 370, BIOSPACE, Republic of Korea). The analyzer performs impedance measurements across five body segments (right arm, left arm, trunk, right leg, and left leg) using three different frequencies (5, 50, and 500 kHz), and provides separate body mass readings for each segment. The device provides separate body mass readings for different body segments, being able to estimate the basal metabolic rate. The basal metabolic rate is directly proportional to the weight and amount of muscle. It was calculated from predictive formulas using the results of the body composition, and involves the data of age, sex and physical activity that is entered into the scale.
Unit of measure: kilocalories per day (kcal/day).
Measured: Baseline, Week 6, and Week 12
Body Mass Index (BMI)
Body Mass Index (BMI) is a clinical index that is used in bioimpedance to assess a person's weight. BMI is calculated by dividing the weight (in kg) by the height (in meters) squared.
Unit of measure: kilograms per square meter (kg/m²).
Measured: Baseline, Week 6, and Week 12
Waist-to-Hip Ratio (WHR)
The ratio of the circumference of the waist to the circumference of the hips, used as an indicator of cardiovascular risk. WHR was calculated by dividing the waist circumference in centimeters by the hip circumference. It is an element for the prognosis of cardiovascular events in adults. The cut-off index for cardiovascular risk is less than 0.85 for women and 0.90 for men. The unit of measurement is unitless.
Unit of measure: kilograms per square meter (kg/m²).
Measured: Baseline, Week 6, and Week 12
Waist-to-Height Ratio (WHtR)
The ratio of the circumference of the waist to height, used as an indicator of metabolic and cardiovascular risk. Height was measured using a vertical stadiometer graduated in centimeters and millimeters. Waist circumference was assessed using a tape measure graduated in centimeters and millimeters. The tape measure was placed midway between the iliac crest and the last rib. This anatomical point has the strongest correlation with abdominal adiposity. The values obtained were stratified into three categories: between 0.40 and 0.44 (lowest % fat, below the risk threshold); between 0.45 and 0.50 (moderate risk); between 0.50 and 0.56 (above the risk threshold). The unit of measurement is unitless.
Measured: Baseline, Week 6, and Week 12
Conicity Index (CI)
Conicity index is a measure of body fat distribution, particularly visceral fat, calculated using body circumference measurements. The C Index (CI) was determined based on the measurement of body mass, height and waist circumference, in meters, representing an indicator of abdominal obesity, and is based on the principle that some people accumulate fat around the abdomen, with the consequent change in body shape. This index is calculated using the formula:
C Index = waist circumference (m)/(0.109 x (√ body mass (kg)/height (m))).
For the classification of cardiovascular risk, values ≥ 1.18 for women and ≥ 1.25 for men are determined. The unit of measurement is unitless.
Measured: Baseline, Week 6, and Week 12
Anthropometric measures
Anthropometric measurements, as circumferences were assessed to evaluate the distribution of fat and other physical characteristics. The circumference measurements will be taken at the following sites, measured in centimeters (cm): neck, waist, hip, arm, and calf.
Measured: Baseline, Week 6, and Week 12
Functionality
The Timed Up and Go (TUG) test was used to assess functional mobility and dynamic balance. Participants were instructed to stand up from a standard chair, walk 3 m at their usual pace, turn around, walk back to the chair, and sit down. The time required to complete the test was recorded in seconds, with shorter completion times indicating better functional mobility and dynamic balance.
Measured: Baseline, Week 6, and Week 12
Body Shape Index (ABSI)
A Body Shape Index (ABSI) was used to assess body shape by considering waist circumference adjusted for body mass index (BMI) and height. Higher ABSI values indicate greater central adiposity and increased health risk. The cutoff values adopted were 0.0805 for women and 0.0828 for men.
Measured: Baseline, week 6, and week 12
Health-related quality of life
Each participant completed the 36-Item Short Form Health Survey (SF-36) before the first and after the last intervention session. The SF-36 is a 36-item questionnaire that assesses health-related quality of life across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores for each domain range from 0 to 100, with higher scores indicating better perceived health status and quality of life.
Measured: Baseline, week 6, and week 12
Muscle strength
Handgrip strength was assessed using a Lafayette Hand Dynamometer (Model J00105). Participants were seated with their feet flat on the floor, the shoulder adducted, the elbow flexed at 90°, the forearm in a neutral position, and the wrist extended between 0° and 30°. Three maximal isometric grip contractions, each lasting 3 seconds, were performed with a 60-second rest interval between trials. The highest value recorded was used for analysis.
Isometric lower limb muscle strength was assessed using a Lafayette digital dynamometer (Model 01165A). Hip flexion, hip extension, hip external rotation, knee flexion, and knee extension were evaluated through maximal voluntary isometric contractions performed in standardized positions. Stabilization straps were used during testing to minimize compensatory movements and improve measurement reliability. Three trials were performed for each movement, and the mean value was used for analysis.
Measured: Baseline, week , and week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jul 2026
- Study start31 Oct 2024
- Primary completion31 Jan 2026
- Study completion31 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obese AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Laboratorio de Vibraçoes Mecanicas e Praticas Integrativas
- Sponsor type
- University, hospital or other
- Collaborators
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Conselho Nacional de Desenvolvimento Científico e Tecnológico, Rio de Janeiro State University, Rio de Janeiro State Research Supporting Foundation (FAPERJ)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07729215
- Sponsor's protocol ID
- 90160825.6.0000.5259
- Acronym
- SVT
- Status last verified
- Jul 2026
- First submitted
- 22 Jul 2026
- Last updated
- 27 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected IPD supporting the results in publications will be utilized.
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effects of Systemic Vibration Therapy on Thermogenesis, Cardiovascular Parameters, Endocrine-inflammatory Markers, and Physical-functional Performance in Adults With Obesity.
- ClinicalTrials.gov ID
- NCT07729215
- Acronym / sponsor ID
- SVT / 90160825.6.0000.5259
- Conditions
- Obese Adults
- Keywords
- whole-body vibration, systemic vibratory therapy, obesity, functionality, cardiovascular risk, muscle strength, body composition, adults
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Laboratorio de Vibraçoes Mecanicas e Praticas IntegrativasUniversity, hospital or other
- Collaborators
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Conselho Nacional de Desenvolvimento Científico e Tecnológico, Rio de Janeiro State University, Rio de Janeiro State Research Supporting Foundation (FAPERJ)
- Study start
- 31 Oct 2024 (actual)
- Primary completion
- 31 Jan 2026 (actual)
- Study completion
- 31 Jan 2026 (actual)
- First posted
- 27 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial was to evaluate the effects of Systemic Vibration Therapy (SVT) on thermogenesis, cardiovascular health, endocrine-inflammatory markers, and physical performance in adults (men and women, aged 18-59) with obesity. The main questions it aimed to answer were:
What were the effects of SVT on thermogenesis and physical-functional performance in people with obesity?
How did SVT affect cardiovascular risk, hormone levels, and inflammation?
Researchers compared two types of vibrating platforms (vertical and side-alternating) to a placebo group (where the platform was turned off but simulated the sound) to see if the vibration led to changes in these health parameters.
Participants:
Attended sessions 2 times per week for either 6 or 12 weeks.
Stood barefoot in a static squat position on a vibrating platform for 29 minutes per session (alternating 1 minute of vibration with 1 minute of rest).
Underwent health assessments, including blood tests, body composition scans, muscle strength tests, and quality of life questionnaires.
Detailed description
Obesity is characterized by the excessive accumulation of body fat and triggers systemic impacts. Currently, it affects 1 in 8 people worldwide, with projections of generating global costs of US$ 3 trillion per year by 2030. In Brazil, prevalence may reach 30.4%. Central obesity is associated with chronic inflammation, insulin resistance, metabolic dysfunctions, and an increased risk of cardiovascular diseases (CVD), which are the leading causes of death globally. Low-grade inflammation and alterations in the autonomic nervous system also exacerbate cardiovascular risk. In this context, brown adipose tissue, with its thermogenic function, has been studied as a potential ally in body mass control. Excess fat combined with muscle mass loss accentuates functional impairments. Although physical exercise is essential, low adherence among individuals with obesity requires viable alternatives. Systemic vibration therapy (SVT), which utilizes mechanical vibrations through vibrating platforms, emerges as a promising strategy, with evidence of effects on reducing body fat, increasing muscle strength, and modulating hormonal and neuromuscular responses. However, conclusive evidence regarding the best protocols is lacking, justifying further studies.This study aims to evaluate the effects of SVT on thermogenesis, cardiovascular, endocrine-inflammatory parameters, and the physical-functional performance of adults with obesity by applying different protocols. Individuals aged 18 to 59 of both sexes, with a BMI ≥ 30 kg/m² and WHR ≥ 0.50, will be included. Recruitment will take place at HUPE, PPC/UERJ, the general community, and social media. The sample size calculation indicated a need for 30 participants, accounting for potential dropouts. Personal information will be collected, and biochemical, endocrine-inflammatory, vascular, cardiovascular risk, body composition, muscle strength, electromyography, physical-functional tests, eating behavior, quality of life, cognition, sleep, vital signs, and perceived exertion assessments will be performed.Interventions will occur twice a week, with a 72-hour interval, for 6 and 12 weeks. Two types of vibrating platforms will be used: vertical displacement (VVP) and side-alternating displacement (AVP). Three protocols will be applied: the GAVP will use the AVP with a frequency of 30 Hz and an amplitude of 2.5 mm or 5.0 mm; the GVVP will use the VVP, also at 30 Hz with "low" amplitude; and the SG (Sham Group) will perform the same movements with the platform turned off, simulating the vibration sound. In all groups, participants will be barefoot, in a static squat with knees at $50^\circ$, for 1 minute of exposure followed by 1 minute of rest, repeated 15 times, totaling 29 minutes per session.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Side-Alternating Vibratory Platform Group (SAVPG) | Active comparator | Device: Systemic vibratory therapySystemic vibration therapy was performed on a vibrating platform with side-alternating displacement of the base, at a frequency of 30 Hz, with the peak-to-peak displacement adjusted to 2.5 mm or 5.0 mm. The individual was positioned barefoot, standing on the base of the vibrating platform, with the knees flexed at 50° (measured with a goniometer), in a static squat consisting of 1 minute of exposure to vibration followed by 1 minute of rest. This sequence was performed 15 times, totaling 29 minutes. |
| Vertical Vibratory Platform Group (VVPG) | Active comparator | Device: Systemic vibratory therapySystemic vibration therapy was performed on a vibrating platform with vertical displacement of the base, and the individual was positioned barefoot, standing on the base of the vibrating platform with the knees flexed at 50° (measured with a goniometer), at a frequency of 30 Hz, with the amplitude adjusted to "low." The participant was positioned in a static squat, consisting of 1 minute of exposure to mechanical vibration followed by 1 minute of rest. This sequence was performed 15 times, totaling 29 minutes. |
| Control group (CG) | Placebo comparator | Device: Systemic vibration therapyThe individual was positioned barefoot, standing on the base of the side-alternating vibrating platform, with the knees flexed at 50° (measured with a goniometer). The vibrating platform was turned off and coupled with a device that simulated the sound of mechanical vibration. The volunteer performed the simulation in a static squat, consisting of 1 minute of exposure with the device turned on followed by 1 minute of rest with the device turned off. This sequence was performed 15 times, totaling 29 minutes. |
Who may qualify
- Ages
- 18 to 59 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Individuals aged 18 to 59 years;
- Both sexes;
- Diagnosis of obesity, defined as a body mass index (BMI) ≥ 30 kg/m²;
- Waist-to-height ratio (≥ 0.50).
Key exclusion criteria (9 listed)
- Presence of metallic prostheses;
- Presence of a pacemaker;
- Uncontrolled and untreated hypertension (≥180/120 mmHg);
- History of labyrinthitis;
- Previous diagnosis of deep vein thrombosis;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Systemic vibratory therapyAlso: vibrating platformThe vertical displacement vibrating platform (Power Plate Pro 5, North America, Inc.) used features triplanar movement of its base (up and down, right and left, and forward and backward movements). However, the resultant of these movements is vertical; therefore, the individual felt as if it performed only the up and down movement while undergoing systemic vibration therapy. In this equipment, the frequency could be adjusted, and the amplitude was selected according to the chosen frequency, such as "high" or "low." The side-alternating displacement vibrating platform (KIKOS FITNESS, model P204IXC, São Paulo) that was used features base movements like a "seesaw," where the right side rises while the left side lowers and vice versa (in relation to the central fulcrum). On this equipment, the individual felt as if they were on a "seesaw." On this vibrating platform, the frequency could be adjusted, and the amplitude was selected according to the positioning of the individual's. | Device | Side-Alternating Vibratory Platform Group (SAVPG), Vertical Vibratory Platform Group (VVPG) |
| Systemic vibration therapyAlso: vibrating platformThe individual was positioned barefoot, standing on the base of the side-alternating vibrating platform. The vibrating platform was turned off and coupled with a device that simulated the sound of mechanical vibration. | Device | Control group (CG) |
Primary outcome
Thermogenin
Time frame: Baseline, Week 6, and Week 12
Thermogenin (Uncoupling Protein 1 [UCP1]) was measured before and immediately after the WBV session. Blood samples were collected by a trained professional at the PPC/UERJ Clinical Analysis Laboratory (Capsule Unit), always during the same morning shift and no later than 8:00 a.m. For peripheral blood assays, serum and plasma collection tubes were centrifuged at 2,000 rpm at 25°C. Subsequently, 500 µL of serum was aliquoted into two microtubes and stored at -80°C until analysis. Serum UCP1 concentrations were determined using a specific enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. Optical density (OD) was measured using a Thermo Scientific spectrophotometer.
Endocrine-inflammatory profile
Time frame: Baseline, Week 6, and Week 12
The endocrine-inflammatory profile was assessed by measuring Interleukin-1 beta (IL-1β), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Tumor Necrosis Factor-alpha (TNF-α), Soluble TNF Receptor Type I (sTNF-RI), Soluble TNF Receptor Type II (sTNF-RII), adiponectin, resistin, leptin, and irisin. Blood samples were collected by a trained professional at the PPC/UERJ Clinical Analysis Laboratory (Capsule Unit), always during the same morning shift and no later than 8:00 a.m. For peripheral blood assays, serum and plasma collection tubes were centrifuged at 2,000 rpm at 25°C. Subsequently, 500 µL of serum was aliquoted into two microtubes and stored at -80°C until analysis. Biomarker concentrations were determined using specific enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions. Optical density (OD) was measured using a Thermo Scientific spectrophotometer.
13 secondary outcomes
Total Body Water
Time frame: Baseline, Week 6, and Week 12
Lean Body Mass, Fat Mass, and Skeletal Muscle Mass
Time frame: Baseline, Week 6, and Week 12.
Body Fat Percentage
Time frame: Baseline, Week 6, and Week 12
Basal Metabolic Rate
Time frame: Baseline, Week 6, and Week 12
Body Mass Index (BMI)
Time frame: Baseline, Week 6, and Week 12
Waist-to-Hip Ratio (WHR)
Time frame: Baseline, Week 6, and Week 12
Waist-to-Height Ratio (WHtR)
Time frame: Baseline, Week 6, and Week 12
Conicity Index (CI)
Time frame: Baseline, Week 6, and Week 12
Anthropometric measures
Time frame: Baseline, Week 6, and Week 12
Functionality
Time frame: Baseline, Week 6, and Week 12
Body Shape Index (ABSI)
Time frame: Baseline, week 6, and week 12
Health-related quality of life
Time frame: Baseline, week 6, and week 12
Muscle strength
Time frame: Baseline, week , and week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2026.
- Individual participant dataSharing planned: Yes. All collected IPD supporting the results in publications will be utilized.
Related trials for Obese Adults
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
RecruitingPhase 3
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
Obesity
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Systemic vibratory therapy and Systemic vibration therapy in people with Obese Adults, run by Laboratorio de Vibraçoes Mecanicas e Praticas Integrativas at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Thermogenin (time frame: Baseline, Week 6, and Week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.